Endonovo Therapeutics Receives Final Commissioned Report

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment

LOS ANGELES, CA--(Marketwired - Dec 2, 2014) - Endonovo Therapeutics, Inc. ( OTCQB : ENDV ) ("Endonovo" or the "Company"), a biotechnology company developing innovative regenerative therapies, has received a final report from Emergo Group, Inc. ("Emergo") that reviewed, classified and recommended Endonovo's strategy for gaining FDA 510K regulatory clearance of their proprietary bioelectronic technology for the treatment of urinary incontinence in women. 

The Company also announced that Randolph M. Johnson, Ph.D. has been appointed by the Company as its Executive Vice President, Clinical Development and Chief Development Officer, effective immediately, to lead its device clinical product development and regulatory clearance.

Alan Collier, Chief Executive Officer and Chairman of Endonovo Therapeutics, commented, "Receiving the Emergo report and its recommendations is an important step and will help structure the best path to market for our proprietary device.

"We are particularly delighted to welcome Dr. Randolph Johnson to Endonovo at this key juncture in the Company's development. His over two decades experience in drug discovery and development, new drug delivery initiatives and research with Amgen, Roche and other firms will be beneficial as we develop and implement our FDA regulatory pathway."

"Dr. Johnson's expertise and abilities will greatly assist us in the development and ultimate commercialization of 'cell-free' therapeutics that can promote the regeneration of tissues without the injection of stem cells into the body, which would result in safer and more effective therapies, lower medical costs and improvement in the quality of life for many women experiencing urinary incontinence."

"I am thrilled to join Endonovo Therapeutics. Studies have demonstrated the ability of Endonovo's proprietary technology to potentially control the embryogenic development process of human cells," stated Dr. Johnson. "The possibility to develop new treatments and therapies that could transform medicine is an extremely attractive opportunity."

Previously Dr. Johnson was President and Chief Executive Officer of Innov8r Therapeutics, a Stanford University oncology startup. Prior, he was Chief of Technology Development and Vice President of Research at KAI Pharmaceuticals, Inc., where he led the discovery, engineering and early development of velcalcetide™, a novel therapeutic approach for the treatment of secondary hyperparathyroidism in hemodialysis patients. That discovery in part led to KAI's acquisition by Amgen ( NASDAQ : AMGN ) where he subsequently served as Scientific Executive Director. Dr. Johnson previously served at Roche Bioscience as Department Head of Molecular & Cellular Biochemistry, Center for Biological Research.

Dr. Johnson is a patented inventor named on 12 U.S. and international patents filed and/or issued, for therapeutic products for pain, drug delivery and treatment of inflammatory diseases. He has authored over 115 scientific publications, abstracts, and book chapters. 

Dr. Johnson earned his Ph.D. in Biomedical Sciences-Pharmacology at University of South Carolina School of Medicine. He was a Postdoctoral Research Fellow and Research Assistant Professor, Department of Pharmacology at University of Virginia School of Medicine and received his M.A. in Biology and B.S. in Zoology at California State University Long Beach. 

About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a publicly traded biotechnology company developing off-the-shelf, cell free regenerative products and non-invasive, bioelectronic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged due to disease and age. The Company is developing therapies for various inflammatory, autoimmune and degenerative diseases using proprietary technology and biomolecules secreted from cells.

Safe Harbor Statement This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact : Mr. Steven Barnes Vice President of Investor Relations Endonovo Therapeutics, Inc. Tel: 800-701-1223 Ext. 108 E-Mail: sbarnes@endonovo.com Website: www.endonovo.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 51

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 29

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading
Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 105

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 12

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 73

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 32

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 87

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 121

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 60

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 62

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading

Top 5 Most Recently Viewed Articles

Ryan Debenham Steps Up as New CEO of GRIN to Drive Growth

Updated Category News Views 312

Ryan Debenham Takes Leadership Role at GRIN GRIN, a leading creator management platform, has announced an exciting transition in leadership with Ryan Debenham becoming the new CEO. Previously serving as the company's president, Debenham's promotion marks a significant step for GRIN as it aims to enhance its offerings and deepen its engagement with brand partnerships....

Continue Reading
Impetus Wellness Group Launches Innovative VMS Platform

Updated Category News Views 282

Impetus Wellness Group Launches Innovative VMS Platform Impetus Wellness Group has just announced an exciting new venture enabled by a strategic partnership with Reliance Vitamin. This collaboration is set to elevate the wellness industry, especially in the realm of vitamins, minerals, and supplements (VMS). Leadership Structure and Vision At the helm of Impetus is a...

Continue Reading
MEXC Ventures Collaborates with Solana ANZ for Web3 Event

Updated Category News Views 211

MEXC Ventures and Solana ANZ: A New Era for Web3 Events MEXC Ventures has made a significant entry into the Web3 ecosystem by partnering with Solana ANZ to host the Web3 Builders and Traders Night. This collaboration takes place in a vibrant locale, signifying MEXC Ventures' commitment to the growth of the blockchain community. A Successful Gathering of Web3 Professionals...

Continue Reading
Investors Take Action: Join the Sable Offshore Securities Case

Updated Category News Views 212

Investors Have a Unique Opportunity in Sable Offshore Case Many investors have encountered challenges in the stock market, particularly with the case involving Sable Offshore Corp. (NYSE: SOC). The situation has prompted a significant response from the legal community, aiming to support those impacted. Faruqi & Faruqi, LLP, a renowned national securities law firm, is...

Continue Reading
Kaplan Achieves Double Recognition in Education Equity Awards

Updated Category News Views 193

Kaplan's Remarkable Achievement in Educational Equity Recently, Kaplan has been honored as a double winner in the prestigious American Consortium for Equity in Education's 2024 Excellence in Equity – Industry Impact Awards. This recognition is significant, highlighting Kaplan's outstanding contributions in two important categories: Company of the Year - Higher Education...

Continue Reading